Timing Matters in Prostate Cancer Treatment

Prostate cancer patients undergoing radiotherapy may experience late side-effects like rectal bleeding and urinary incontinence. Researchers have been exploring the connection between the body's internal clock and the effectiveness of cancer treatment. They found that certain genetic variations in the PER3 gene, which regulate our circadian rhythms, can impact how patients respond to radiotherapy at different times of day.

A large-scale study involving 1760 prostate cancer patients from various countries was conducted to investigate this further. The patients received external beam radiotherapy and were monitored for two years. By analyzing the data, researchers discovered that the time of day when radiotherapy was administered interacted with specific genetic genotypes to affect the risk of side-effects. For instance, patients with a particular genetic variation in the PER3 gene who received treatment in the morning were more likely to experience rectal bleeding compared to those treated in the late afternoon.

The study's findings suggest that by taking into account a patient's genetic makeup and the timing of their treatment, doctors may be able to minimize side-effects and improve their quality of life. This approach, known as chronomodulation, could lead to more personalized and effective treatment plans. For example, patients with a certain genetic variation could benefit from avoiding treatment during peak hours to reduce their risk of urinary incontinence.

The results of this study support previous research on breast cancer patients, highlighting the importance of considering the interplay between genetics, circadian rhythms, and treatment timing. By exploring this connection further, researchers hope to develop more targeted and efficient treatment strategies that prioritize patient well-being.